Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 - Clinical Trial Not Allowed)
Funding Opportunity PAR-18-734 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. (Source: NIH Funding Opportunitie...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 30, 2018 Category: Research Source Type: funding

Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)
Funding Opportunity PAR-18-733 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and u...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 30, 2018 Category: Research Source Type: funding

Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-718 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding

Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-719 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and h...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding

NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)
Funding Opportunity PAR-18-726 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically-trained vision scientists for independent research careers. This initiative is intended to expand and strengthen the community of investigators engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve a pool of scientists with contemporary, multidisciplinary expertise able to leverage rec...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding

BRAIN Initiative: New Technologies and Novel Approaches for Large-Scale Recording and Modulation in the Nervous System (R01 Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-18-020 from the NIH Guide for Grants and Contracts. Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for largescale recording and manipulation of neural activity to enable transformative understanding of dynamic signaling in the nervous system. In particular, we seek exceptionally creative approaches to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 14, 2018 Category: Research Source Type: funding

BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01-Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-18-019 from the NIH Guide for Grants and Contracts. Although invention and proof-of-concept testing of new technologies are a key component of the BRAIN Initiative, to achieve their potential these technologies must also be optimized through feedback from end-users in the context of the intended experimental use. This seeks applications for the optimization of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in any r...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 14, 2018 Category: Research Source Type: funding

Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional)
Funding Opportunity PAR-18-689 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 1, 2018 Category: Research Source Type: funding

Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional)
Funding Opportunity PAR-18-690 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 1, 2018 Category: Research Source Type: funding

Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional)
Funding Opportunity PAR-18-691 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 1, 2018 Category: Research Source Type: funding

Notice of NIGMS Participation in PA-18-610 "Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R43/R44 Clinical Trial Not Allowed)"
Notice NOT-GM-18-020 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 23, 2018 Category: Research Source Type: funding

Notice of NIGMS Participation in PA-18-609 Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R41/R42 Clinical Trial Not Allowed)
Notice NOT-GM-18-019 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 23, 2018 Category: Research Source Type: funding

Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-669 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to provide continuing support for specific pathogen free (SPF) macaque colonies previously funded under the auspices of PAR-14-066. Breeding colonies are essential to sustain Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Pedigree SPF macaques are free of certain viruses, which can confound the results of AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major hist...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 21, 2018 Category: Research Source Type: funding

Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-660 from the NIH Guide for Grants and Contracts. The goal of this FOA is to develop new hypotheses and common experimental framework(s) between human - animal model studies to better understand the genetic, genomic, and epigenetic factors contributing to and underlying biological bases for the development of tolerance and the progression to alcohol dependence. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 14, 2018 Category: Research Source Type: funding

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-655 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 13, 2018 Category: Research Source Type: funding

Basic Research in Cancer Health Disparities (R01 Clinical Trials Not Allowed)
Funding Opportunity PAR-18-654 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 13, 2018 Category: Research Source Type: funding

Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-622 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to solicit hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 1, 2018 Category: Research Source Type: funding

Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (U01 Clinical Trial Optional)
Funding Opportunity PAR-18-616 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity Announcement (FOA) is to support research projects using a Traceback approach to genetic testing to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 1, 2018 Category: Research Source Type: funding

Notice of Pre-Application Webinar for PAR-18-583 "Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)"
Notice NOT-RM-18-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 1, 2018 Category: Research Source Type: funding

Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity PA-18-610 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications from small business concerns for Small Business Innovation Research (SBIR) projects that propose innovative research and development of technology for cryogenic or other long-term preservation and revival of Drosophila and zebrafish genetic stocks. The proposed technologies should be reliable, reproducible and cost effective for the long-term preservation and revival of wild type and laboratory created genetic stocks. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 31, 2018 Category: Research Source Type: funding

Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R41/R42 Clinical Trial Not Allowed)
Funding Opportunity PA-18-609 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications from small business concerns for Small Business Technology Transfer (STTR) projects that propose innovative research and development of technology for cryogenic or other long-term preservation and revival of Drosophila and zebrafish genetic stocks. The proposed technologies should be reliable, reproducible and cost effective for the long-term preservation and revival of wild type and laboratory created genetic stocks. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 31, 2018 Category: Research Source Type: funding

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trials Not Allowed)
Funding Opportunity PAR-18-583 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transc...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 16, 2018 Category: Research Source Type: funding

Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-018: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 Clinical Trial Optional)
Notice NOT-DK-18-008 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 11, 2018 Category: Research Source Type: funding

Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-017: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Optional)
Notice NOT-DK-18-007 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 11, 2018 Category: Research Source Type: funding

Sensory and motor system changes as predictors of preclinical Alzheimers disease (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-18-519 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimers disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal coho...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 20, 2017 Category: Research Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-17-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. T...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 19, 2017 Category: Research Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)
Funding Opportunity RFA-DK-17-018 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. T...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 19, 2017 Category: Research Source Type: funding

Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-18-516 from the NIH Guide for Grants and Contracts. The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimers disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of A...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 19, 2017 Category: Research Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related...
Source: NIDDK Funding Opportunities - December 19, 2017 Category: Endocrinology Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related...
Source: NIDDK Funding Opportunities - December 19, 2017 Category: Endocrinology Source Type: funding

Sleep disorders and circadian clock disruption in Alzheimers disease and other dementias of aging (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-497 from the NIH Guide for Grants and Contracts. This FOA is aimed at molecular, cellular, genetic, epigenetic, and systems biology approaches to advance basic and clinical research on the causes and consequences of sleep deficiency and circadian clock dysfunction in Alzheimer's disease, and the roles of sleep and the circadian clock as modifiers of the progression of neurodegeneration. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 15, 2017 Category: Research Source Type: funding

From Association to Function in the Alzheimers Disease Post-Genomics Era (R01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits innovative and collaborative research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimers disease (AD). Specifically, NIA is interested in identifying and developing more effective and integrated platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants prior to...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 15, 2017 Category: Research Source Type: funding

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Funding Opportunity PAR-18-226 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2017 Category: Research Source Type: funding

Notice of Intent to Publish a Funding Opportunity Announcement for Genetics of Tolerance (R01- Clinical Trial Not Allowed)
Notice NOT-AA-17-016 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2017 Category: Research Source Type: funding

Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21- Clinical Trial Required)
Funding Opportunity PA-18-405 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages the submission of pilot and feasibility therapeutic trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes. This FOA is not...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 21, 2017 Category: Research Source Type: funding

Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21- Clinical Trial Required)
This Funding Opportunity Announcement encourages the submission of pilot and feasibility therapeutic trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes. This FOA is not appropriate for mechanistic clinical trials. (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 21, 2017 Category: Endocrinology Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 15, 2017 Category: Research Source Type: funding

Fertility Status as a Marker for Overall Health (R21 Clinical Trial Optional)
Funding Opportunity PA-18-049 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with oth...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 15, 2017 Category: Research Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this prog...
Source: NIDDK Funding Opportunities - November 15, 2017 Category: Endocrinology Source Type: funding

Reducing Health Disparities Among Minority and Underserved Children (R21 Clinical Trial Optional)
Funding Opportunity PA-18-169 from the NIH Guide for Grants and Contracts. This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific healt...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2017 Category: Research Source Type: funding

Reducing Health Disparities Among Minority and Underserved Children (R01 Clinical Trial Optional)
Funding Opportunity PA-18-152 from the NIH Guide for Grants and Contracts. This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific healt...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2017 Category: Research Source Type: funding

Systems Biology Approaches using Non-Mammalian Laboratory Animals to Uncover Causes of Neurodegeneration that Might Underlie Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-18-021 from the NIH Guide for Grants and Contracts. The National Institute on Aging is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias. Importantly, a major goal of this FOA is to use inter...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 6, 2017 Category: Research Source Type: funding

Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)
Funding Opportunity PAR-18-090 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disor...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2017 Category: Research Source Type: funding

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional)
Funding Opportunity PA-18-057 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage the application of Big Data analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance abuse and addiction.NIDA recognizes that to accelerate progress toward understanding how the human brain and behavior is altered by chronic drug use and addiction, it is vital to develop more powerful analytical methods and visualization tools that can help capture the richness of data being generated from genetic, epigenetic, molecular, proteomic, metabolomic, brain-...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2017 Category: Research Source Type: funding

Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)
This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field.In addition, for som...
Source: NIDDK Funding Opportunities - November 1, 2017 Category: Endocrinology Source Type: funding

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50)
Funding Opportunity PAR-18-313 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are conside...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 12, 2017 Category: Research Source Type: funding

Notice of Change to Foreign Component Eligibility in RFA-NS-18-001 "Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54)"
Notice NOT-NS-18-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 26, 2017 Category: Research Source Type: funding

Notice of Change in Application Due Dates for RFA-NS-18-001 "Center Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54)"
Notice NOT-NS-18-010 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 22, 2017 Category: Research Source Type: funding

Population-Based Model Organism Research for G x E Exploration in Complex Disease Outcomes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-17-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research using population-based model organism resources for environmental health science and toxicology questions. This FOA is particularly interested in the interplay between environment, genetics, and epigenetics and the identification and understanding of host susceptibility to environmental exposures, relevant to human disease outcomes. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2017 Category: Research Source Type: funding

High Impact Neuroscience Research Resource Grants (R24)
Funding Opportunity RFA-NS-18-006 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers. Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery. Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of r...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2017 Category: Research Source Type: funding